CHINA NBS OFFICIAL: EXPECTS MACRO POLICY MEASURES AFTER POLITBURO MEETING TO GAIN TRACTION
China has solid conditions to achieve annual growth target - NBS
New home prices in China's first-tier cities stayed relatively flat in July, NBS data showed today. Shanghai, Guangzhou, and Shenzhen saw new home prices climb by 0.2%, 0.1%, and 0.2%, respectively, from June, while Beijing reported a dip of 0.3%.
Show more
China's value-added industrial output grew 4.5% in July from a year earlier, the NBS said today. The figure increased 5.3% in the first seven months from the same period a year ago.
Show more
A FULL ACCOUNT OF MR. OFWONO OPONDO’S CRIME OF UTMOST SAVAGERY AT THE NBS TV FRONTLINE TALKSHOW
China's urban unemployment rate averaged 5.2% in the first seven months, within the annual target of 5.5%, according to data released by the NBS today. In July alone, the figure rose 0.2 percentage points from the previous month to 5.2% due to seasonal factors.
Show more
China's fixed asset investment slumped 6.7% in the first seven months from a year earlier to CNY26.03 trillion (USD3.86 trillion), the NBS said today. Investment in intellectual property jumped 9.1%, while private fixed-asset investment plunged 9.4%.
Show more
China’s retail sales of consumer goods climbed 1.2% in the first seven months from the same period last year to CNY28.78 trillion (USD4.27 trillion), the NBS said today. Excluding automobiles, the figure advanced 2.7% to CNY26.51 trillion (USD3.93 trillion). Retail sales of consumer goods edged up 0.6% to CNY3.9 trillion (USD578 billion) in July.
Show more
Naturally pretty but when I put myself together it's a different type of pretty going on. Nbs
GENEDX $WGS Q3’26 EARNINGS HIGHLIGHTS
🔹 Revenue: $123.1M (Est. $123M) 🟡; +5% YoY
🔹 Adj. EPS: $0.28 (Est. $0.07) 🟢
🔹 GAAP EPS: -$0.41
🔹 Exome & Genome Revenue: $110.4M; +12% YoY
🔹 Exome & Genome Volume: 32,134; +25% YoY
🔹 Non-GAAP Gross Margin: 72%; -200 bps YoY
FY26 Guide:
🔹 Revenue: $475M-$490M (Est. $482M) 🟡
🔹 Exome & Genome Revenue Growth: At least 17%
🔹 Exome & Genome Volume Growth: At least 28%
🔹 Adjusted Gross Margin: ~71%
🔹 Adjusted Net Income: ~$12M
Q4 Guide:
🔹 Revenue: $135M
🔹 Exome & Genome Revenue: $121M
🔹 Exome & Genome Volume: 34,500 tests
🔹 Adjusted Gross Margin: At least 71%
🔹 Adjusted Net Income: ~$12M
Customers & Assets:
🔹 Accession Growth: +28% YoY
Announcements:
🔹 GUARDIAN Study: 30,000 newborns enrolled; 72.3% parental participation
🔹 BRIDGES-NBS: Screen up to 30,000 newborns for 700+ conditions over two years
Key Updates:
🔹 Adjusted Net Income: $8.6M
🔹 Medicaid Coverage: 25 state programs now cover whole genome sequencing
🔹 ASHG: 27 scientific abstracts presented
Comments:
🔸 “Our Q3 results reflect profitable execution in a growing market, as we translate the rising demand for exome and genome testing into durable revenue growth”
🔸 “Our priorities are clear: improve the economics of our testing, expand utilization, and deliver leading products at scale.”
Show more